Literature DB >> 1186921

Effect of nafenopin (SU-13,437) on liver function: mechanism of choleretic effect.

W G Levine, H R Braunstein, D K Mejier.   

Abstract

Administration of nafenopin (SU-13-437) to male rats for two days leads to a doubling of bile production and a 50% increase in liver weight. These two effects have been shown not to be directly interrelated. A marked decrease in biliary salt concentration suggests that the bile salt independent flow is stimulated. The extra bile produced is probably of canalicular origin since bile to plasma concentration ratios of erythritol are unchanged. At least three polar metabolites of nafenopin have been observed in rat bile. Observations in rats with partial biliary fistulas indicate that the drug and its metabolites undergo extensive entero-hepatic circulation. Our studies support the view that much of the enhanced bile flow is associated with the presence of nafenopin and/or its metabolites within the hepatobiliary system. However, the response is too extensive to be explained merely by osmotic choleresis. Induced structural changes in the liver may also account forsome of this effect.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1186921     DOI: 10.1007/bf00510552

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  The choleretic potencies of some synthetic compounds.

Authors:  M J GUNTER; K S KIM; D F MAGEE; H RALSTON; A C IVY
Journal:  J Pharmacol Exp Ther       Date:  1950-08       Impact factor: 4.030

Review 2.  Mechanisms and control of secretion of bile water and electrolytes.

Authors:  S Erlinger; D Dhumeaux
Journal:  Gastroenterology       Date:  1974-02       Impact factor: 22.682

3.  Effect of phenobarbital on bile flow and bile salt excretion in the rat.

Authors:  G Paumgartner; W Horak; P Probst; G Grabner
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1971

4.  Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.

Authors:  J Reddy; D Svoboda; D Azarnoff
Journal:  Biochem Biophys Res Commun       Date:  1973-05-15       Impact factor: 3.575

5.  Studies on the increased biliary flow produced by phenobarbital in rats.

Authors:  C D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  1971-03       Impact factor: 4.030

6.  Metabolism of SU-13437--a new hypolipidemic drug in man.

Authors:  J R Bianchine; P Weiss; M J Peaston; R M Hersey; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

7.  Mechanism of phenobarbital-induced hypercholeresis in the rat.

Authors:  P Berthelot; S Erlinger; D Dhumeaux; A M Preaux
Journal:  Am J Physiol       Date:  1970-09

8.  Experimental investigations in cholersis.

Authors:  F W Koss; W Lamprecht
Journal:  Eur J Pharmacol       Date:  1968-09       Impact factor: 4.432

9.  Effect of nafenopin (SU-13,437) on liver functions. Hepatic uptake and biliary excretion of ouabain in the rat.

Authors:  D K Meijer; J Bognacki; W G Levine
Journal:  Drug Metab Dispos       Date:  1975 May-Jun       Impact factor: 3.922

10.  Effect of the hypolipidemic drug nafenopin (2-methyl-2-(p-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy)propionic acid; TPIA; SU-13,437), on the hepatic disposition of foreign compounds in the rat.

Authors:  W G Levine
Journal:  Drug Metab Dispos       Date:  1974 Mar-Apr       Impact factor: 3.922

View more
  2 in total

1.  Effect of nafenopin (SU-13,437) on liver function: influence on the hepatic transport of organic anions.

Authors:  D K Meijer; J Bognacki; W G Levine
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  Bile formation and biliary lipid composition under the influence of clofibrate and phenobarbital pretreatment in the rat.

Authors:  K Kutz; A Schulte; C Just; H Lindstaedt; B Reiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.